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 : ثحبنا تيفهخ حضشع شثكأ نىوىكَ ذق ٌشكسنا ًضشمن لولأا عىىنا ءاقشأ نأ ذجو كنزن شكسنا ضشمت حتاصلإن اُساسأ آسود ٍثاسىنا مماعنا ةعهَ
.شكسنا حُنامرحلا ٌىمفنا صحفنا للارعلا 
 :فدهنااقمو شكسنا ممحذ ساثرخا اوشجا ذق ٌشكسنات هُتاصمنا ءاقشلأا ناك ارإ ام ذَذحرن.حطتاضنا حعىمجمنا عم مهروس 
 : تيجهنمنا ًهع دَشجأ حوساقم حساسد ٍف021  )جشطُسنا حعىمجم و ًنولأا حجسذنا بساقأ ,ٌشكسنا ًضشم ( عُماجم زلاث ًنإ اىمسق صخش
 هم حوىكم حعىمجم مك01 م جشرفهن خىكنا ٍف ٍمُهعرنا ءاشهزنا ًفشرسم ٍف ٌشكسنا زكشم ًنإ مهرعجاشم للاخ اوشُرخا آصخشناسُو ه/2102 
ناسُو ًنإ/2102. 
: جئاتننا (ٌىمفنا شكسنا حُنامرحا صحف ٌشجأOGTT  لا لذعم نؤت جئارىنا خشهظأ و ٌشكسنا ضشمت حتاصم شُغنا عُماجمنا ًنا )OGTT 
(شُثك ٌىىعم قسافت عرمرَsignificant P value 0.000( ٌىىعم قساف ذجىَ لا هُح ٍف هُرعىمجمنا ارهك يذن )non-significant P value 
0.288من فلارخلأا لذعمت )OGTT (ًنولأا حجسذنا بساقأ يذن ًهعأ ناك فلارخلاا لذعم نأ هم مغشنات25.3250 جشطُسنا حعىمجمت حوساقمنات )
(22.0750.)  
: جاتنتسلاا لارعأ اوشهظأ ءاقشلأا نأ نىك  ٌشكسنا ضشمن لولأا عىىنات حتاصلإا هع ِوؤسم نىكَ ذق ٍثاسىنا مماعنا نأ ٌىمفنا صحفنات ِ
 .شكسنا حُنامرحلا 
 : ثايصىتنا( ٌىمفنا شكسنا حُنامرحا صحف يشجَ نأ ةجَ ٌشكسنا ضشمن لولأا عىىنات حتاصلإا هع شكثمنا فشكنا ضشغنOGTT  ءاقشأ مكن )
ضشمنا كنزت هُتاصمنا. 
Abstract: 
Background: the genetic factor of type 1 diabetes mellitus may play a key role in pathogenesis of that disorder, 
thus, diabetic siblings might prone into an impaired OGTT. 
Objective: To determine whether diabetic Siblings might have an impaired glucose tolerance test in compare to 
normal control group. 
Material and Method: A case-control study was performed on 120 persons, they divided into three group 
which are diabetic, siblings and control (40 persons in each group), who attended to Al Zahraa Teaching 
Hospital /Diabetic Center in Al Kut between the period from April; 2012 till April; 2013. 
Results: OGTT performed on both diabetic siblings and control, results have showed that the Means of OGTT is 
highly Significant (P value = 0.000) in both Siblings and Control groups, whereas there were no Significant 
differences in the Means of differences of OGTT in both tested groups (Siblings and Control), P value = 0.288, 
although the Mean of differences of OGTT is higher in Siblings group (25.3250) than that in Control group 
(22.0750). 
Conclusion: the inheritance factor play a key role in pathogenesis of type 1 diabetes mellitus since, diabetic 
siblings showed an impaired OGTT. 
Recommendation: for early detection of diabetes, diabetic siblings must submit to a routine screening test by 
OGGT.  
Key words: Type 1 diabetes mellitus, Siblings, OGTT. 
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INTRODUCTION 
Type 1 diabetes is an autoimmune disorder in which the destruction of insulin-
producing beta-cells can be detected years before the clinical manifestation of the disease 
[1].
 
Selective autoantibody assays and metabolic testing can now identify first degree relatives of 
type I diabetic patients, in whom the risk of diabetes is over 80% at 5 years 
[2,3].
 The ability to 
identify subjects at risk makes the exploration of immune intervention strategies to halt or 
even prevent Beta-cell destruction a major goal. The clinical manifestation of type 1 diabetes 
usually involves symptoms such as polyuria and polydipsia and is thought to occur after 
autoimmune destruction of most of the pancreatic B-cells, resulting in severe insulin 
deficiency and fasting hyperglycemia. However, investigators in the Diabetes Prevention 
Trial of Type 1 Diabetes (DPT-1) 
[4,5] 
have detected a group of subjects with type 1 diabetes 
who have a different phenotype. These subjects are asymptomatic, have normal (<6.1 mmol/l) 
or impaired (6.1–<7.0 mmol/l) fasting glucose on their oral glucose tolerance tests (OGTTs), 
but have 2-h glucose values >11.1 mmol/l, thus meeting one of the American Diabetes 
Association’s [6] new criteria for the diagnosis of diabetes. Importantly, these subjects have 
characteristics placing them at increased risk for type 1 diabetes; i.e., they are relatives of 
patients with type 1 diabetes, they are <45 years of age, and they are islet cell antibody (ICA)-
positive. The DPT-1 is a multicenter randomized trial designed to determine if type 1 
Diabetes can be prevented or delayed. First- or second-degree relatives of type 1 diabetic 
patients ≤ 45 years of age are screened for the presence of ICAs. Then, those who are ICA+ 
enter the staging part of the DPT-1, during which they undergo tests to estimate their risk for 
developing diabetes more precisely. The last staging test performed before randomization into 
the treatment part of their study there is an OGTT to rule out the presence of diabetes 
[4, 5].
 
Those with fasting or postprandial hyperglycemia on this OGTT are excluded from further 
participation. This report describes the population of subjects with type 1 diabetes identified 
by the 2-h OGTT criteria alone at the time of the DPT-1 staging OGTT. Demographic data 
(age, sex, and relationship to proband), immune activity (antibody status), and tests of B-cell 
function (first-phase insulin response [FPIR] and OGTT) are described for these subjects and 
compared with those subjects whose staging OGTT for DPT-1 classified them as having 
normal glucose tolerance (NGT) or impaired glucose tolerance (IGT).Carla J. et al., (2001), 
[7]
 
describe a previously unrecognized group of subjects with asymptomatic type 1 diabetes. 
These subjects have normal or impaired fasting glucose values and elevated 2-h glucose 
values on OGTT. The validity of their observation is indicated by the fact that there is no 
absolute difference or trend of higher values in fasting glucose among those with NGT, IGT, 
and diabetes diagnosed by 2-h glucose alone, despite moderate (IGT) or marked (diabetic) 2-h 
hyperglycemia. In addition, repeat OGTT was performed on 14 subjects with diabetes 
diagnosed by 2-h OGTT criteria alone, and either IGT or diabetes with normal fasting glucose 
was confirmed in 13 of the subjects. Importantly, these subjects have characteristics 
associated with type 1 diabetes; they are relatives of subjects with type 1 diabetes, they are 
between 3 and 45 years of age, they are ICA+, and 53% have markedly abnormal first-phase 
insulin release. Although the use of FPG is simpler and more reproducible 
[8, 9],
 the omission 
of the 2-h PG will miss a proportion of diabetic subjects who have normal FPG but elevated 
2-h PG (> or equal to 11.1 mmol/l) 
[10]
. They have suggested using the paired values of FPG 
and HbA1c to identify potential diabetic subjects [11](Ko GTC. Only those with high FPG 
(6.1–6.9 mmol/l) and high HbA1c ( > or equal to 6.1%) required an OGTT to confirm 
diabetes. With use of this approach, > 80% of OGTTs could be saved 
[12]
. Hence, they 
followed up on 208 nondiabetic subjects and examined their rates of progression to diabetes. 
They analyzed their likelihood of becoming diabetic according to their baseline FPG and 
HbA1c concentrations. 
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OBJECTIVE:  
To determine whether diabetic Siblings might have an impaired glucose tolerance test in 
compare to normal control group. 
PATIENTS AND METHOD 
This study was performed on 120 persons, selected randomly with matched age and sex, 
with male to female ratio ½, who were attended to Al Zahraa Teaching Hospital /Diabetic 
Center in Al Kut between the periods from April, 2012 till April, 2013. 
• Three study groups were investigated which included: 
• First group: Forty patients with IDDM, fulfilling inclusion criteria for IDDM (1. 
younger age less than 35 yrs., 2. Positive family history. 3. Positive HLA association. 4. 
Autoimmune association and Positive antibody to B-cells (ICA). 5. Low BMI less than 
18.5, 6.FBS >120 mg/dl , RBS >180-200 mg/dl and HbA1c > 6  plus clinical signs and 
symptoms) [12] 
• Second group: Forty relatives (Sibling) of IDDM patients had no history or clinical 
evidence of IDDM or any autoimmune disease. 
• Third group: Forty healthy control group who had no history or clinical evidence of 
IDDM or any autoimmune disease. 
Oral glucose tolerance test were performed for both Diabetic Siblings and Control 
groups using a Glucose powder manufactured by the State Company for the Drugs Industry 
and Medical Appliances Samarra-Iraq. 
Preparation before the test:  
1. Unrestricted carbohydrate diet for 3 days. 
2. Fasted overnight for at least 8 hrs. 
3. Rest for 30 mins. 
4. Remain seated for the duration of the test, with no smoking. 
Sampling:  
Plasma glucose is measured before and 2 hrs after a 75 g oral glucose drink [13]. 
RESULTS: 
Table (1): OGTT before and after 75 g of oral glucose drink in Siblings group: 









1.1325E2 40 23.50095 3.71583 
Table (1) show the Data that collected and tested by Independent sample T-test and 
Paired T-test. Results showed that the means of OGTT is highly significant (P value = 0.000) 
in between siblings and control groups, whereas there were no significant differences in the 
means of differences of OGTT in both tested groups (siblings and control), P value = 0.288, 
although the mean of differences of OGTT is higher in siblings group (25.3250) than that in 
control group (22.0750). 
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Table (2): OGTT before and after 75 g of oral glucose drink in Control group: 





91.7000 40 15.28733 2.41714  
0.000 
OGTT 2hrs  
after 
1.1378E2 40 21.28378 3.36526 
Table (2) show the Data that collected and tested by Independent sample T-test and 
Paired T-test. Results showed that the means of OGTT is highly significant (P value = 0.000) 
in between siblings and control groups, whereas there were no significant differences in the 
means of differences of OGTT in both tested groups (siblings and control), P value = 0.288, 
although the mean of differences of OGTT is higher in siblings group (25.3250) than that in 
control group (22.0750). 
Table (3): Means of differences in OGTT between Sibling and Control group: 
Group No. Mean of 
difference 
OGTT 
Std. Deviation Std. Error Mean P.value 
sibling 40 25.3250 15.37295 2.43068 0.288 
control 40 22.0750 11.54120 1.82482 0.288 
Table (3) show the Data that collected and tested by Independent sample T-test and 
Paired T-test. Results showed that the means of OGTT is highly significant (P value = 0.000) 
in between siblings and control groups, whereas there were no significant differences in the 
means of differences of OGTT in both tested groups (siblings and control), P value = 0.288, 
although the mean of differences of OGTT is higher in siblings group (25.3250) than that in 
control group (22.0750), Table (3.3, 3.4, and 3.5). 
 
 
Figure (1): Means of differences in OGTT between Sibling and Control group: 
Figure (1) shows the mean of differences in OGTT among both diabetic siblings and 
control that is higher in sibling group than that in control group. 
DISCUSSION: 
The results in this study showed that the means of OGTT is highly significant (P value 
= 0.000) in between siblings and control groups, whereas there were no significant differences 
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in the means of differences of OGTT in both tested groups (siblings and control), P value = 
0.288, although the mean of differences of OGTT is higher in siblings group (25.3250) than 
that in control group (22.0750), Table (1, 2 and 3).These results agreed with Bingley PJ. et 
al., (1994),  Verge CF. et al., (1996), whom stated that selective autoantibody assays and 
metabolic testing could now identify first degree relatives of type I diabetic patients, in whom 
the risk of diabetes is over 80% at 5 years 
[2,3]
. The ability to identify subjects at risk makes 
the exploration of immune intervention strategies to halt or even prevent beta-cell destruction 
a major goal. The investigators in the diabetes prevention trial of type 1 diabetes (DPT-1) 
have detected a group of subjects with type 1 diabetes who have a different phenotype 
[4, 5]
. 
These subjects are asymptomatic, have normal (<6.1 mmol/l) or impaired (6.1–<7.0 mmol/l) 
fasting glucose on their oral glucose tolerance tests (OGTTs), but have 2-h glucose values 
>11.1 mmol/l, thus meeting one of the American diabetes association’s new criteria for the 
diagnosis of diabetes, importantly, these subjects have characteristics placing them at 
increased risk for type 1 diabetes; i.e., they are relatives of patients with type 1 diabetes, they 
are <45 years of age, and they are islet cell antibody (ICA)-positive 
[6].
 This is totally agreed 
with the results that obtained in our study.  
The agreement is going with those results obtained by Carla J. et al., (2001), who 
describe a previously unrecognized group of subjects, with asymptomatic type 1 diabetes. 
These subjects had normal or impaired fasting glucose values and elevated 2-h glucose values 
on OGTT. The validity of their observation is indicated by the fact that there is no absolute 
difference or trend of higher values in fasting glucose among those with NGT, IGT, and 
diabetes diagnosed by 2-h glucose alone, despite moderate (IGT) or marked (diabetic) 2-h 
hyperglycemia. In addition, repeated OGTT was performed on 14 subjects with diabetes 
diagnosed by 2-h OGTT criteria alone, and either IGT or diabetes with normal fasting glucose 
was confirmed in 13 of the subjects. Importantly, these subjects have characteristics 
associated with type 1 diabetes; they were relatives of subjects with type 1 diabetes, between 
3 and 45 years of age, ICA+, and 53% of them had markedly abnormal first-phase insulin 
release 
[7].
 The results that obtained in the present study is not going with New Zealand 
Screaning System of Diabetes (NZSSD)  which now recommends the use of HbA1c to 
diagnose diabetes in most circumstances. Compared with the oral glucose tolerance test 
(OGTT) or fasting glucose alone, HbA1c offers substantial advantages of the lack of need for 
fasting, reduced biological variability and an equally good relationship with increased 
retinopathy and CVD risk 
[14, 15].
 The glucose-based criteria are also limited by high variability 
of blood glucose, particularly for the 2-hour value post OGTT. There are also issues relating 
to sample collection, processing and analytical requirements that are often poorly addressed. 
There is also concern regarding the validity of the standard 75g OGTT for all ages, sizes and 
genders. OGTTs are more expensive than HbA1c, as well as being laborious and time 
consuming for both patients and laboratories. HbA1c however can be misleading in some 
circumstances – e.g. falsely low in patients with increased red blood cell turnover or post 
blood transfusion and falsely high in some haemoglobinopathies as well as some ethnic 
differences in rate of Hbglycation 
[16]
. The current glucose-based diagnostic criteria remain 
unchanged, but the NZSSD recommends that the OGTT should only be used when there is 
uncertainty about the validity of HbA1c measures in specific patients - for example in the 
presence of haemoglobinopathy or abnormal red cell turnover - or where there are special 
clinical reasons.Because the performance of an oral glucose tolerance test (OGTT) is time 
consuming, laborious, and poorly reproducible 
[17, 18, 11].
The american diabetes association 
(ADA) recently recommended a moving away from the OGTT to using fasting plasma 
glucose (FPG) as a diagnostic criterion 
[6]
, which seems to be disagreed with results that 
obtained in our study which showed a potential advantage of the use of OGTT in detection of 
high risk group from the first degree relatives in suspicion of diabetic thus, the omission of 
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the 2-h PG will miss a proportion of diabetic subjects who have normal FPG but elevated 2-h 
PG (> or equal to 11.1 mmol/l) 
[10]
. Also the results of this study were disagreed with Ko 
GTC. et al., (1998), who had suggested the using of the paired values of FPG and HbA1c to 
identify potential diabetic subjects.  
Only those with high FPG (6.1–6.9 mmol/l) and high HbA1c ( > or equal to 6.1%) 
required an OGTT to confirm diabetes. With the use of this approach, > 80% of OGTTs could 
be saved 
[11]
. They followed up 208 nondiabetic subjects and examined their rates of 
progression to diabetes. They analyzed their likelihood of becoming diabetic according to 
their baseline FPG and HbA1c concentrations, which seemed to be not related to OGTT 
results in our study. 
CONCLUSION 
Diabetic Siblings are more liable for development of diabetes in future since the mean 
of OGTT higher in them rather than control group. 
RECOMMENDATION 
OGTT should be included as screening test to elicit the highly risky group from diabetic 
Siblings. 
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